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Incidence and Predictors of Drug-Eluting
Stent Fracture in Human Coronary Artery
A Pathologic Analysis
Gaku Nakazawa, MD,* Aloke V. Finn, MD,† Marc Vorpahl, MD,* Elena Ladich, MD,*
Robert Kutys, MS,* Isidora Balazs, BS,* Frank D. Kolodgie, PHD,* Renu Virmani, MD*
Gaithersburg, Maryland; and Atlanta, Georgia
Objectives The aim of this study was to perform pathologic assessment on stent fracture.
Background Clinically, stent fracture has been reported in 1% to 2% of patients after drug-eluting stent (DES) implantation.
Methods High-contrast film-based radiographs of 177 consecutive lesions from the CVPath DES autopsy registry were re-
viewed. Stent fracture was graded as I (single-strut fracture), II (2 struts), III (2 struts with deformation), IV
(with transection without gap), and V (with transection causing gap in stent segment). The incidence of adverse
pathologic findings (thrombosis and restenosis) was assessed histologically.
Results Stent fracture was documented in 51 lesions (29%; grade I  10, II  14, III  12, IV  6, and V  9). Le-
sions with stent fracture had longer duration after implantation (172 days [interquartile range (IQR) 31 to
630 days] vs. 44 days [IQR 7 to 270 days], p  0.004), a higher rate of Cypher (Cordis Corp., Miami Lakes,
Florida) stent usage (63% vs. 36%, p  0.001), longer stent length (30.0 mm [IQR 22.0 to 40.0 mm] vs.
20.0 mm [IQR 14.0 to 27.3 mm], p  0.0001), and a higher rate of overlapping stents (45% vs. 22%, p 
0.003). Although fracture with grade I to IV did not have significant impact on the occurrence of adverse
pathologic findings such as thrombosis and restenosis, 67% of the grade V fracture lesions were associated
with adverse pathologic findings at fracture sites. Longer stent length, use of Cypher, and longer duration of
implant were identified as independent risk factors of stent fracture by logistic regression analysis.
Conclusions The incidence of stent fracture was 29% lesions at autopsy, which is much higher than clinically reported. A high
rate of adverse pathologic findings was observed in lesions with grade V stent fracture, whereas fracture with
grade I to IV did not have a significant impact on the pathological outcome. (J Am Coll Cardiol 2009;54:
1924–31) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.075a
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cfter pivotal clinical trials comparing bare-metal stents (BMS)
o polymer-based sirolimus (Cypher, Cordis Corp., Miami
akes, Florida) and paclitaxel (Taxus, Boston Scientific,
atick, Massachusetts) stents demonstrated a significant re-
uction in rate of restenosis, drug-eluting stents (DES) quickly
ecame the standard of care for the percutaneous treatment of
ymptomatic coronary artery disease (1,2). Although late stent
hrombosis has been raised as a safety concern in DES (3–5),
he incidence of restenosis has dramatically decreased and is
eported generally as 5%. However, stent fracture has emerged
rom the *CVPath Institute, Inc., Gaithersburg, Maryland; and the †Emory
niversity School of Medicine, Atlanta, Georgia. Dr. Finn has received research
unding from Boston Scientific. Dr. Virmani receives research support from
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cal, Biotronik, and Alchimedics; and is a consultant for Medtronic AVE, Abbott
ascular, Prescient Medical, and Biotronik.h
Manuscript received December 8, 2008; revised manuscript received April 23,
009, accepted May 5, 2009.s a complication following DES implantation and is recog-
ized as one of the contributors of in-stent restenosis (6–8)
nd possibly stent thrombosis (9,10). Clinically, the incidence
f stent fracture is reported in 1% to 2% of patients at 8- to
0-month follow-up angiography (6,11). However, because of
See page 1932
imited sensitivity of angiography to detect fracture, its true
ncidence is still unknown. The aim of this study was to assess
he incidence of stent fracture at autopsy using high-contrast
lm-based radiography and to investigate the impact of stent
racture on the pathologic findings and clinical outcomes.
ethods
tudy population and histologic preparation. The study
omprised of 144 autopsy cases with 200 DES lesions. All
earts and/or coronary arteries had been fixed in 10%
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November 17, 2009:1924–31 Pathologic Analysis of Drug-Eluting Stent Fractureuffered formalin. A whole heart was X-rayed using high-
ontrast film-based radiography (Faxitron 43855A, Fax-
tron X-Ray, Lincolnshire, Illinois) in anterior-posterior
iew (70 to 75 kVp/15 s) when a whole heart was available.
picardial coronary arteries were then dissected from the
eart and re-X-rayed at a lower kilovolt potential setting (40
Vp/15 s). Stented arteries were submitted for plastic
mbedding and serially cross-sectioned at 2- to 3-mm
ntervals. All sections were stained with hematoxylin and
osin and Movat pentachrome as previously described
4,12).
ssessment of stent fracture and pathologic sections. All
adiographs of stented vessels were assessed by light micros-
opy at 40 magnification. Stents with artifacts were
xcluded, including those that had been cut, distorted, or
rushed during the removal of the vessel from the heart or
ere received in pieces. Stent length and extent of overlap
as determined by examining the radiographs. Strut frac-
ure was defined as complete transection of a strut. The
resence of stent fracture was recorded and classified as
rade I to V: I  involving a single-strut fracture; II  2 or
ore strut fractures without deformation; III  2 or more
trut fractures with deformation; IV  multiple strut frac-
ures with acquired transection but without gap; and V 
ultiple strut fractures with acquired transection with gap
None M
B  Calcification
A  Fracture
I II
Figure 1 Representative Images of Stent Fracture and Calcifica
(A) Grade I fracture of Taxus stent (single-strut fracture), grade II fracture of Cyphe
(multiple breaks with deformation), grade IV fracture of Cypher stent (multiple breaks w
Arrows indicate fractured stents. (B) Classification of calcification (mild: focal calcifica
with calcification). Arrows indicate areas of calcification.n the stent body (Fig. 1A). The
everity of calcification in the
tented lesion was also recorded
s none, mild (calcification barely
een or focally localized; 25%
tented segment), moderate
multiple sites of calcification), or
evere (highly visible diffuse cal-
ification; 70% stented seg-
ent) (Fig. 1B).
To correlate the pathologic
ndings and stent fracture, histo-
ogic sections were also reviewed. The presence of acute
hrombus was defined as a platelet-rich thrombus that occu-
ied 30% of the cross-sectional area of the lumen, and
estenosis was defined as75% cross-sectional area narrowing
y neointimal formation within the stented segment. In all
ases of stent fracture, an attempt was made to section the area
f the fracture. In cases with thrombosis or restenosis, the
elationship between these adverse pathologic findings and the
ite of fracture was recorded (i.e., histologic finding in sections
t the fracture site or close to fracture site). In addition,
istologic comparisons were performed between stents
ith fracture versus without. Furthermore, the same
omparisons were made between various fracture grades.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
IVUS  intravascular
ultrasound
LCx  left circumflex
coronary artery
RCA  right coronary
artery
     Moderate     Severe
IV V
t (multiple breaks but alignment is preserved), grade III fracture of Cypher stent
nsection but without gap), and grade V fracture of Cypher stent (total separation).
oderate: multiple sites of calcification; severe: 75% of stent length is associatedild 
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Pathologic Analysis of Drug-Eluting Stent Fracture November 17, 2009:1924–31eointimal thickness, fibrin deposition, and inflamma-
ory reaction, including giant cell and eosinophil infiltra-
ion, were assessed as previously described (4,5).
tatistical analysis. Continuous variables with normal dis-
ribution were expressed as mean  SD. Continuous
ariables with non-normal distribution were expressed as
edian and interquartile range (IQR). Comparisons be-
ween fracture and nonfracture lesion were tested by Stu-
ent t test for normally distributed continuous variables and
hi-square test for categorical values. A Wilcoxon rank sum
est was used for comparisons of non-normally distributed
arameters or discrete variables. Normality of distribution
as tested with the Wilk-Shapiro test. For multiple logistic
egression analysis, a forward stepwise method was used to
etect independent predictors of stent fracture. Variables in
able 1 with p  0.05 were entered into the analysis, and
hose with p 0.10 were removed. A value of p 0.05 was
onsidered statistically significant.
esults
ncidence of stent fracture. Twenty-three lesions were
xcluded because of artifacts that were observed when we
eceived the samples. In the remaining 177 lesions, stent
racture was documented in 51 lesions (29%) (grade I  9,
atient and Lesion CharacteristicsTable 1 Patient and Lesion Characteristics
Fracture ()
42 Patients,
51 Lesions
Fracture ()
98 Patients,
126 Lesions p Value
Age, yrs 64 13 61 13 0.17
Male 33 (79) 75 (77) 0.99
Cause of death
Stent-related death 16 (38) 36 (37)
Nonstent cardiac death 13 (31) 29 (30) 0.98
Noncardiac death 11 (26) 29 (30)
Surgically explanted heart 2 (5) 4 (4)
Cypher/Taxus 32/19 45/82* 0.001
Duration (days) 172 (31–630) 44 (7–270) 0.004
30 days 42 (82) 87 (69) 0.07
Lesion location
LMCA 3 (6) 5 (4) 0.23
LAD 18 (35) 60 (48)
LCx 8 (16) 26 (21)
RCA 16 (31) 29 (23)
Graft 6 (12) 6 (5)
Stent length (mm) 30.0 (22.0–40.0) 20.0 (14.0–27.3) 0.0001
Number of stents 1.7 0.9 1.3 0.6 0.0008
Overlapping 23 (45) 28 (22) 0.003
Bifurcation 8 (16) 19 (15) 0.99
Vessel calcification
None 7 (14) 28 (22) 0.08
Mild 21 (41) 46 (37)
Moderate 20 (39) 32 (25)
Severe 3 (6) 20 (16)
alues are mean  SD, n (%), or median (interquartile range). *1 lesion received both Cypher and
axus stents.p
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; LMCA 
eft main coronary artery; RCA  right coronary artery.I  14, III  11, IV  6, and V  9). Most of the fractures
n the Cypher stents were located in flexible N-shaped,
ndulating longitudinal intersinusoidal-ring linker segments,
hereas in Taxus Express stents, fractures were observed in the
traight longitudinal intercrown linker or the modular ring
ortion (13). Furthermore, in single-stented lesions, the ma-
ority of stent fractures were localized in the middle portion of
he stent body, except for stents 25-mm length where the
racture sites were slightly shifted toward the proximal portion
Fig. 2A). On the other hand, in overlapping stents, most
ractures were observed within 5-mm distance from the over-
apping zone, with similar frequency in proximal and distal
egions (Fig. 2B). Mean age and sex of patients were not
ifferent between lesions with versus without fracture
Table 1). There was no significant difference in cause of death
etween patients with fracture and those without. Lesions with
tent fracture had longer duration of stent implants (fracture;
72 days [IQR 31 to 630 days] vs. nonfracture; 44 days [IQR
to 270 days], p  0.004). There was no statistical difference
n stent implant duration between each stent fracture of grade
grade I: 31 days [IQR 5 to 616 days], II: 105 days [IQR 27 to
,095 days], III: 376 days [IQR 72 to 570 days], IV: 331 days
IQR 31 to 833 days], and V: 172 days [IQR 44 to 450 days],
B
A
Figure 2 Distribution of Location of Stent Fracture
in Nonoverlapping and Overlapping Stents
(A) Location of stent fracture in nonoverlapping stent. Note, the majority of
stent fractures were localized in the middle of the stent body, except for stents
25-mm length where the fracture sites were slightly shifted toward the proxi-
mal end. (B) In overlapping stents, most fractures were observed within 5-mm
distance from the overlapping zone with similar frequency in proximal and dis-
tal regions. 0.70). Furthermore, lesions with stent fracture showed a
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November 17, 2009:1924–31 Pathologic Analysis of Drug-Eluting Stent Fractureigher rate of Cypher stent usage (63% vs. 36%, p  0.001),
onger stent length (30.0 mm [IQR 22.0 to 40.0 mm] vs. 20.0
m [IQR 14.0 to 27.3 mm], p  0.0001), greater number of
tents (1.7  0.9 vs. 1.3  0.6, p  0.008), and a higher rate
f overlapping stents (45% vs. 22%, p  0.003). However,
here were no statistical differences in severity of vessel
alcification between the 2 groups. Stent fractures were
ore commonly found in the right coronary artery
RCA) and in bypass grafts, but this did not reach
tatistical significance. Longer stent length (p  0.0001,
dds ratio [OR]: 1.07, 95% confidence interval [CI]:
.036 to 1.100), use of Cypher stent (p  0.002, OR:
.40, 95% CI: 1.57 to 7.33), and longer duration (p  0.002,
R: 1.002, 95% CI: 1.001 to 1.003) were identified as
ndependent risk factors of stent fractures by a forward stepwise
ogistic regression analysis.
istologic comparison between fracture and nonfracture
esions. Neointimal thickness was similar between stents
ith fracture (0.11 mm [IQR 0.06 to 0.19 mm]) and
ithout (0.11 mm [IQR 0.03 to 0.19 mm], p  0.62).
here was no significant difference in fibrin deposition
fibrin score: fracture (); 1.0 [IQR 0.1 to 1.5] vs. fracture
); 1.4 [IQR 0.4 to 2.0]) and inflammation (inflammatory
core: fracture (); 1.0 [IQR 0.5 to 1.6] vs. fracture (); 1.4
IQR 0.4 to 2.0]) including a similar degree of giant cell and
osinophil infiltration. Furthermore, no differences in these
arameters among various fracture grades (i.e., grades I to
, data not shown).
orrelation to adverse pathologic findings. Six adverse
athologic findings (5 thrombosis and 1 restenosis) were
ssociated with grade V fracture (67%), whereas there were
o fracture site-related adverse pathologic findings in stents
ith grades I to IV except for 1 stented lesion with grade IV
p  0.0001 vs. grade V) (Table 2). Total rates of adverse
ype of Fracture and Clinical OutcomesTable 2 Type of Fracture and Clinical Outcomes
Grade
I
(n  10)
Stent type, Cypher/Taxus 1/9
Adverse pathologic findings, n (%)
Associated with fracture site 0 (0)
Irrespective of fracture 4 (40)
Restenosis 0 (0)
Thrombosis 4 (40)
Other underlying pathologic factors associated with thrombosis
Acute myocardial infarction indication —
Bifurcation —
Long/overlapping stenting 2
Dissection/medial fracture 1
Malapposition —
Underexpansion 1
Hypersensitivity —
Others —1 lesion received both Cypher and Taxus stents; †p 0.0001 versus grade I to IV; ‡p 0.03 versus fractu
easons.athologic findings irrespective of fracture severity were
imilar between lesions with fracture and those without
35% vs. 37%, p  0.99). However, stents with grade V
racture showed a significantly higher rate of adverse patho-
ogic findings as compared with those without fracture (78%
s. 37%, p  0.03) (Table 2).
Cases with grade V fracture are listed in Table 3. A
8-year-old-female (Case 1), who died of late stent
hrombosis in the left circumflex coronary artery (LCx),
ad 2 stents in the LCx/left obtuse marginal branch
LOM) bifurcation. Both LCx (Taxus) and LOM
Cypher) stents showed grade V fracture. Taxus stent
racture in LCx was located in the area close to the
ifurcation site and was near the thrombus, which ex-
ended into the bifurcation site, whereas the Cypher stent
n LOM had restenosis at the site of fracture (Fig. 3).
he Taxus stent was distorted at the fracture site, and
ome struts protruded into the lumen where thrombus
as observed. Cypher stent, on the other hand, showed
oderate chronic inflammation, including macrophages
nd lymphocytes at the site of fracture. A 60-year-old
ale (Case 2) with grade V Cypher stent fracture had
hest pain 60 days following stent placement and under-
ent angiography. Stent thrombosis was detected by
ngiography, which was treated by balloon angioplasty
ollowed by bypass surgery; however, the patient died
rom surgical complications. The histologic sections at
he fracture site showed fragment of thrombus with
oderate fibrin deposition and inflammatory cell infil-
ration, including macrophages, giant cells, and occa-
ional neutrophils. A 58-year-old male (Case 3) who died
f subacute stent thrombosis 11 days following stent
mplantation showed complete separation of the Cypher
tent distal to the site of overlap with thrombotic
Fracture ()
Fracture ()
(n  126)
I
14)
III
(n  12)
IV
(n  6)
V
(n  9)
Total
(n  51)
/4 10/2 5/1 6/3 32/19 45/82*
) 0 (0) 0 (0) 6 (67)† 6 (12) NA
1) 3 (25) 1 (17) 7 (78)‡ 18 (35) 46 (37)
) 0 (0) 0 (0) 1 (11) 1 (2) 5 (4)
1) 3 (25) 1 (17) 6 (67) 17 (33) 42 (33)
2 — — 3 10
— — 1 2 11
— 1 1 4 3
— — — 2 2
— — — — 2
— — 1 2 —
1 — — 1 3
— — 3 3 11§I
(n 
10
0 (0
3 (2
0 (0
3 (2
1
1
—
1
—
—
—
—re () group; §includes thrombosis with isolated uncovered struts, septic thrombus, and unknown
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Pathologic Analysis of Drug-Eluting Stent Fracture November 17, 2009:1924–31cclusion. At the site fracture, the stent was underex-
anded, and thrombus was observed in the lumen (Fig. 4).
owever, there was no significant difference in vascular
eaction, such as fibrin deposition and inflammation,
etween fracture and nonfracture sites. Another 83-year-
ld male (Case 4) who died 27 days following Taxus stent
mplantation, had a stent fracture that showed septic
hrombotic occlusion in the distal portion of 4 overlap-
ing stents. The thrombotic occlusion was observed, not
nly at the fracture site, but extended into the proximal
tents, and was thought to have lodged at the site of
racture related to the infection. A 57-year-old male
Case 5) who died of diffuse coronary artery disease had
Cypher stent placed in the distal RCA 1.800 days ante
ortem. The stent showed a transection with a gap, and
istology revealed chronic total occlusion with organized
hrombus at the site of fracture. A 71-year-old male
Case 6) who died with late stent thrombosis had a long
axus stent implanted in the RCA, and a thrombus was
bserved only in the proximal portion, whereas grade V
tent fracture was located in the middle portion of the
tent. A Cypher stent in a 68-year-old male (Case 7) had
rade V fracture; however, the vessel was widely patent at
70 days, and the patient died of severe coronary artery
isease in nonstented segments (Fig. 5). A 62-year-old
ale (Case 8) received 2 Cypher stents 130 days ante
ortem and died of diffuse coronary artery disease. The
ypher stent showed an acquired transection distal to the
verlapping site with a gap. Histologic section showed
idely patent lumen at the fracture site and mild fibrin
eposition with minimal inflammation, including macro-
hages and lymphocytes.
iscussion
ain findings in the present study are: 1) a higher rate of
tent fracture in DES at autopsy (29%) than what has been
linically reported; 2) a higher event rate was observed in
esions with grade V stent fracture, whereas grade I to IV
racture showed no significant impact on the clinical out-
ome; and 3) longer stent length, Cypher stent usage, and
onger stent duration of implant were identified as indepen-
ent predictors of stent fracture.
The incidence of stent fracture has been reported to be
% to 2% in clinical settings (6,7). In the current study, stent
racture was observed in 29% of lesions, which is far more
requent compared with what was reported clinically. The
eason for the higher detection rate of fracture is due to the
se of a high-contrast film-based radiography that allowed
s to detect even minor stent fracture in contrast to poor
isibility by angiography or intravascular ultrasound (IVUS)
ecause of insufficient resolution. The resolution of a
igh-contrast film-based radiography is reported as 80
m, which is greater than that of angiography (300 m) or
VUS (200 m). Our findings suggested that there are a fair
number of patients who have “subclinical,” low-grade stentEi
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November 17, 2009:1924–31 Pathologic Analysis of Drug-Eluting Stent Fractureracture that remains clinically silent. However, 9 lesions
5.1%) were associated with grade V fractures (i.e., complete
eparation) in the present study. Given that only severe
ractures with gap can be detected by angiography, the
ncidence of fracture with grade V in the current study is
ithin expectations and consistent with previous clinical
eports.
Although the stent fracture was more frequently docu-
ented in our population, the incidence of adverse patho-
ogic findings was similar between stents with and without
racture when all grades of fractures were included. This
ould be explained by the study population since ours is an
utopsy study and therefore might have a higher incidence
f DES failures in both groups. However, if only grade V
ractures are included, stent fracture is associated with a
ignificantly higher rate of adverse pathologic findings as
ompared with nonfracture group as well as fracture with
rade I to IV. We observed 6 adverse pathologic findings at
he fracture sites (5 stent thrombosis and 1 restenosis)
mong 9 grade V fracture lesions (67%) in the present study.
lthough it is not fully understood why stent fractures cause
dverse events, the lack of stent integrity, such as distortion
r acquired underexpansion, may also play an important role
LOM
LCX
A
B
C
D
A (i)
(ii)
Figure 3 A Case of Grade V Cypher and Taxus Stent Fracture (
At 172 days following implantation the patient died from stent thrombosis in the l
left obtuse marginal (LOM) artery. Note, presence of grade V Cypher stent fracture
in the Taxus stent (ii). (B) Cypher stent in LOM with grade V fracture was associa
the bifurcation site where the thrombus was located (Thr). (D) The stented LCx sen occurrence of adverse events as shown in some of our sases. In additional analysis, no significant pathological
ifferences (i.e., inflammation, giant cell reaction, and fibrin
eposition) were observed between stents with and without
racture, as well as among the various fracture grades.
lthough stent fracture clinically has been reported to
redominantly be associated with restenosis, we had a
igher incidence of acute thrombus in our study. Neverthe-
ess, some case reports have described cases of stent throm-
osis with stent fracture (9,10).
Previous clinical studies have reported that the main risk
actors for stent fracture are longer stent length, RCA or
aphenous vein graft lesion location, lesion with high
otion, overlapping stent, and Cypher stent use (6,8,14).
lthough actual stent angulations or motion on the heart
ould not be assessed in the present study, the risk factors
dentified in the present study are similar to those reported
linically. Cypher stent was associated with higher incidence
f stent fracture; the flexible N-shaped, undulating longi-
udinal intersinusoidal-ring linker segment was the most
requent location of the fractures, which are smaller in width
han the sinusoidal-ring portion. RCA and bypass graft
esions were also more common in the fracture group than
n the nonfracture group but did not reach statistical
B
C
D
Thr
LOM
LOM LCX
LCX
1 in Table 3)
umflex coronary artery (LCx). (A) Radiograph of the stented left circumflex and
ghted in magnified image (i) and another grade V fracture at the bifurcation site
h restenosis. (C) Taxus stent fracture in LCx was located in the area close to
distal to the fracture was widely patent.Case
eft circ
highli
ted wit
gmentignificance because of the small number of cases in the
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Pathologic Analysis of Drug-Eluting Stent Fracture November 17, 2009:1924–31resent study. On the other hand, the time course of stent
racture has not been investigated in clinical studies, since
rst follow-up angiography is usually planned at 8 to 12
onths. In the present study, longer implant duration was
dentified as an independent risk factor for stent fracture,
hus suggesting that stent fracture may result from contin-
ous stress over time to the implant, which leads to greater
etal fatigue with eventual fracture. However, it should also
e noted that stent fracture was seen even in the patients
ho died shortly after stent implantation, which is probably
rocedure-related (high pressure and/or oversized balloon,
verlapping stent, and so on).
tudy limitations. Because this is an autopsy study, the
esults may not be representative of all patients who receive
ES. Our population is biased toward patients dying from
ES complications. Stent thrombosis and restenosis rates
n our registry are considerably higher than those reported in
linical settings. Furthermore, vessel motion, tortuosity, and
ngulations on the beating heart, which also play an
mportant role in stent fracture (15), cannot be assessed.
he mechanisms of adverse pathologic findings in grade V
racture could not be elucidated by histologic assessment in
he present study, probably because of the small sample size
thr
LM OL
A
C
C D
E
D
Figure 4 A Case of Grade V Cypher Fracture With Subacute Th
(A) Radiograph of the left anterior descending coronary artery (LAD) shows an ove
(highlighted in B). (C and D) Histologic sections of the overlapping stents showed
The section taken at the fracture site showed an underexpansion of the stent with
region.nd time variation at autopsy. Unlike clinical or preclinical atudies, the timing for the observation in autopsy studies
annot be controlled. In fact, the stent implant durations in
rade V fracture range from 11 to 1,800 days. However, to
he best of our knowledge, this is the first report of stent
racture in a large series assessed at autopsy with a highly
ensitive method, and therefore, the findings in the present
tudy remain valid and represent a more accurate assessment
f fracture incidence than either angiography or IVUS.
onclusions
he incidence of DES fracture is 29% of the stented lesions
t autopsy, which is much higher than clinically reported. A
igh rate of adverse pathologic findings was observed in
esions with grade V fracture, whereas grade I to IV fracture
id not have significant impact on the clinical outcome.
onger stent length, Cypher stent usage, and longer dura-
ion of stent implant were identified as independent predic-
ors of stent fracture.
cknowledgment
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mplete separation was observed just proximal to the overlapping site, but histo-
ypher stent with grade V fracture located just proximal to the overlapping site
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